TScan Therapeutics Inc. operates as a clinical-stage biotechnology company focused on the development of T-cell receptor-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's primary function is to harness the power of the immune system to battle various forms of cancer through innovative TCR-T technology. By engineering T cells to recognize and attack tumor cells, TScan aims to provide novel treatment options for patients with unmet medical needs. TScan Therapeutics is particularly significant in the fields of oncology and immunotherapy, where it targets several types of malignancies, including solid tumors and hematological cancers. The biotech firm conducts extensive research and trials to advance its pipeline of therapeutic candidates, which could potentially revolutionize cancer treatment paradigms. With its headquarters located in Waltham, Massachusetts, TScan Therapeutics plays a vital role in the ongoing exploration and development of immune-oncology therapies, contributing to a greater understanding of T-cell engineering in combatting cancer.